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SUMMARY
The Hypogonadism in Males study estimated the preva-
lence of hypogonadism [total testosterone (TT)
0300 ng/dl] in men aged  45 years visiting primary
care practices in the United States. A blood sample was
obtained between 8 AM and noon and assayed for TT,
free testosterone (FT) and bioavailable testosterone
(BAT). Common symptoms of hypogonadism, comorbid
conditions, demographics and reason for visit were recor-
ded. Of 2162 patients, 836 were hypogonadal, with 80
receiving testosterone. Crude prevalence rate of hypogo-
nadism was 38.7%. Similar trends were observed for FT
and BAT. Among men not receiving testosterone, 756
(36.3%) were hypogonadal; odds ratios for having hypo-
gonadism were signiﬁcantly higher in men with hyperten-
sion (1.84), hyperlipidaemia (1.47), diabetes (2.09),
obesity (2.38), prostate disease (1.29) and asthma or
chronic obstructive pulmonary disease (1.40) than in
men without these conditions. The prevalence of hypogo-
nadism was 38.7% in men aged  45 years presenting to
primary care ofﬁces.
Keywords: Epidemiology; testosterone; hypogonadism;
hyperlipidaemia; hypertension; diabetes
ª 2006 Blackwell Publishing Ltd
INTRODUCTION
Hypogonadism in men, characterised by a reduced concen-
tration of serum testosterone, causes a constellation of signs
and symptoms that may include decreased libido, erectile
dysfunction, decreased volume of ejaculate, loss of body and
facial hair, weakness, decreased bone density, decreased lean
body mass, increased body fat, fatigue and anaemia (1,2).
Hypogonadism in adult men is often overlooked, even in
the presence of associated symptoms, because hypogonadal
men often ignore their symptoms or attribute them to alter-
nate causes, including ageing (1).
Unlike female menopause, which is a universal and
abrupt process associated with aging, not all men become
testosterone deﬁcient with ageing. A signiﬁcant number of
men remain eugonadal even with advanced age (3). How-
ever, as men age, they become increasingly likely to have
conditions, such as cardiovascular disease, depression, osteo-
porosis and diabetes that occur concomitantly with
decreased testosterone levels (1).
The impact of hypogonadism on morbidity is largely
unknown because there are few data from large cross-sec-
tional studies that address this aspect. However, small epide-
miological studies point towards an association of
hypogonadism with morbidity resulting from low testoster-
one states in ageing men (4–6). For example, a higher pre-
valence of depression (4,5), osteoporosis, fracture and frailty
(6) have been linked to testosterone deﬁciency. There are
no well-deﬁned criteria for deﬁning hypogonadism based on
total testosterone (TT) concentrations (1), and the clinical
criteria for testosterone deﬁciency remain ambiguous (7–
10). However, Vermeulen has deﬁned hypogonadism as 2.5
standard deviations (SD) below the mean normal TT value
in young adults (627 ng/dl with 1 SD equal to 123 ng/dl),
or 319 ng/dl (9). Hypogonadism deﬁned as TT 0300 ng/
dl has been shown to be related to decreased bone mineral
density (1). Other investigators, using similar criteria (2.5th
percentile), but different data sets, have deﬁned hypogona-
dism as TT 0325 ng/dl (10).
The goal of this study was to estimate the prevalence of
hypogonadism in men aged at least 45 years presenting (for
any reason) to primary care practices in the United States.
A second objective was to correlate the presence of hypogo-
nadism with select comorbid conditions and symptoms.
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internal medicine) were selected as appropriate settings to
estimate the prevalence of hypogonadism because those
practices are usually the initial site for health maintenance
in most adult men. Prevalence rate estimates for hypogo-
nadal and eugonadal men along with corresponding odds
ratios and conﬁdence intervals (CIs) for age, race, current
symptoms and comorbid conditions were also calculated.
METHODS
Clinicians from a random sample of 2650 primary care prac-
tices throughout the United States were contacted and 130
practices agreed to participate. All men aged 45 years and
older who were seen in a participating doctor’s ofﬁce between
8 AM and noon during a 2-week period, regardless of the rea-
son for their visit, were invited to participate in the survey.
To be eligible to participate in this study, men had to meet
the following inclusion criteria: age 45 years or older; ability
to provide a blood sample; and willingness to answer a brief
set of questions related to medical history, social history, con-
comitant medications, and hypogonadal signs and symptoms.
The patients had to be able to read, speak and understand
English. The only speciﬁed exclusion was inability or unwill-
ingness to sign the informed consent form.
The study protocol and the written patient informed con-
sent form were approved by a central Institutional Review
Board (IRB) that complied with the IRB regulations (21
CFR Part 56). Written approval of the study was obtained
from the IRB before the study was implemented. Each
patient read and signed the informed consent form before
their participation in the study.
All eligible patients underwent a serum testosterone assess-
ment by a single morning blood draw (between 8 AM and
noon) to test for concentrations of TT, free testosterone (FT),
bioavailable testosterone (BAT) and sex hormone-binding
globulin (SHBG). All serum samples were analysed by Esoter-
ix Endocrinology (Calabasas Hills, CA, USA). SHBG was
evaluated using radioimmunoassay (RIA). TT was deter-
mined by RIA after extraction of testosterone from human
serum. FT was determined by equilibrium dialysis and scintil-
lation counting through the use of a radiolabelled tracer to
determine the percentage of testosterone in the free form.
BAT was determined through ammonium sulphate precipita-
tion of the SHBG-bound fraction of testosterone, followed by
scintillation counting of a radioactive tracer to determine the
percentage of TT in bioavailable form. The FT percentage
and BAT percentage values are then multiplied by the TT to
derive the FT and BAT concentrations respectively.
For the purpose of this study, hypogonadism was deﬁned
as TT 0300 ng/dl. This value is the middle of the TT
range (200–400 ng/dl) deﬁned as potentially hypogonadal
by the American Association of Clinical Endocrinologists (1)
and is slightly lower than the normal reference range of
350–1030 ng/dl for the laboratory assay used in the study.
The threshold TT concentration that triggers hypogonadal
symptoms varies considerably between individuals, ranging
from very low to above the lower limit of the normal refer-
ence range (2). Given the lack of a widely accepted single
threshold value of TT to deﬁne hypogonadism, 0300 ng/
dl, which has been used in clinical studies of hypogonadal
men, seemed a reasonable choice. TT concentrations were
compared to determine whether there were differences
between early morning (8–10 AM) and later morning
(10 AM–noon) measurements. For all patients, demographic
characteristics, medical history, social history, comorbid con-
ditions and concomitant medications were recorded by the
doctor on case report forms. In addition, all patients were
interviewed to determine whether they were experiencing the
symptoms associated with hypogonadism, including decline
in general feeling of well-being, decrease in muscular
strength, feeling of weakness, physical exhaustion, lacking
vitality, decrease in sexual desire or libido, decrease in ability
to perform sexually and depressed mood. All doctors recor-
ded these symptoms using a standardised case report form.
Target enrolment was 2000 patients. A patient was con-
sidered to be hypogonadal if he had a TT level of
0300 ng/dl, or if he was previously diagnosed as hypogo-
nadal and was receiving androgen treatment, regardless of
his measured testosterone concentration.
The primary statistical analyses focused on descriptive sta-
tistics and prevalence estimation. Hypogonadal prevalence
estimates (with 95% CIs) were obtained for subgroups of
patients derived from demographic variables and other
potential underlying risk factors. The prevalence CIs were
obtained using SAS
TM (SAS Institute Inc., Cary, NC, USA)
PROC FREQ with the BINOMIAL options.
Secondary, exploratory analyses were conducted to assess
the impact of demographic variables and identify potential
risk factors for the prevalence of hypogonadism. Odds ratios
and the corresponding 95% CIs were constructed for these
purposes. The odds ratio reﬂected the increased risk each
evaluated comorbidity carried for hypogonadal sex steroid
concentration results. Odds ratios were obtained using
SAS
TM PROC LOGISTIC software. The CIs were calcula-
ted using the proﬁle likelihood method (CLODDS ¼ PL
option). These factors were further analysed as multiple fac-
tors in SAS
TM PROC LOGISTIC using a stepwise inclu-
sion and elimination procedure. This procedure was used to
examine correlations among the factors. For each factor
remaining in the analysis, the odds ratio and 95% conﬁd-
ence limit were tabulated. The Hosmer–Lemeshow good-
ness-of-ﬁt test was run on the ﬁnal model to check the
model’s adequacy for the data.
Current hypogonadal symptoms were tabulated, and a
chi-square test was conducted comparing hypogonadal with
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tabulated by TT levels and by TT levels in currently treated
patients. Frequency counts were tabulated for categorical
variables; means, SDs, medians and ranges were tabulated
for continuous variables.
RESULTS
Of the 2650 primary care practices throughout the United
States contacted to participate, 95 practices distributed over
25 states enrolled patients. The participating practices were
primarily family medicine (51%) and internal medicine
(42%). Of 2498 men who were solicited to participate,
2165 enrolled in the study (87% acceptance rate) during
the recruitment period from November 2003 to February
2004. The majority of enrolled patients were white (82.2%;
Table 1). The prevalence of hypogonadism was similar for
both white and black participants. The mean age for all
patients was 60.5 years (range, 45–96 years). Most men
(61.6%) were visiting their doctors for routine care
(Table 2).
A higher proportion of hypogonadal patients than eugo-
nadal patients reported a history of hypertension, hyperli-
pidaemia, diabetes and obesity (p 0 0.001 for all of the
conditions; Table 3). All other medical conditions were
reported by 020% of hypogonadal patients and eugonadal
patients.
Figure 1 shows the study population distribution of TT
in 100 ng/dl increments, excluding three patients who did
not have evaluable TT values. The observed range of TT
varied from 50 to 1573 ng/dl. The mean TT concentration
in all patients was 364.8 ng/dl. The mean value of TT was
245.6 ng/dl in hypogonadal patients and 439.9 ng/dl in
Table 1 Baseline characteristics of enrolled patients
Characteristic Hypogonadal patients (n ¼ 836) Eugonadal patients (n ¼ 1326) p-value Total patients* (n ¼ 2165)
Race, n (%) 0.154
White 700 (83.7) 1077 (81.2) 1780 (82.2)
Black 114 (13.6) 180 (13.6) 294 (13.6)
Hispanic 15 (1.8) 42 (3.2) 57 (2.6)
Asian 2 (0.2) 11 (0.8) 13 (0.6)
Other 5 (0.6) 16 (1.2) 21 (1.0)
Mean age, years (SD) 61.6 (10.57) 59.9 (10.11) 0.0003 60.5 (10.33)
Mean BMI, kg/m
2§ (SD) 31.5 (6.06) 28.5 (5.04) 00.0001 29.7 (5.64)
BMI, body mass index; SD, standard deviation. *Evaluable total testosterone values were not available for three patients. Hypogonadal vs. eugonadal, chi-
square test. Hypogonadal vs. eugonadal, t-test. §BMI was not reported in 61 hypogonadal and 80 eugonadal patients.
Table 2 Reason for doctor ofﬁce visit for enrolled patients
Reason for visit Patients (n ¼ 2098)*
General check-up 1293 (61.6)
Cardiovascular 249 (12.0)
Respiratory 163 (8.0)
Skeletal 137 (6.5)
Other 256 (12.1)
Values are expressed as n (%). *Total number of enrolled patients was
2165; however, the reason for the visit was not recorded for 67 patients.
Table 3 Medical history of enrolled
patients with evaluable total testosterone
Condition
Hypogonadal patients
(n ¼ 836)
Eugonadal patients
(n ¼ 1326) p-value*
Hypertension 547 (65.4) 678 (51.1) 00.001
Hyperlipidaemia 506 (60.5) 670 (50.5) 00.001
Diabetes 258 (30.9) 237 (17.9) 00.001
Obesity 270 (32.3) 225 (17.0) 00.001
Prostatic disease/disorder 165 (19.7) 226 (17.0) 0.121
Chronic pain 155 (18.5) 211 (16.0) 0.113
Insomnia/sleep disturbance 129 (15.4) 185 (14.0) 0.342
Asthma/COPD 102 (12.2) 118 (8.9) 0.013
Headaches (within the last 2 weeks) 70 (8.4) 125 (9.4) 0.405
Rheumatoid arthritis 28 (3.3) 29 (2.2) 0.101
Osteoporosis 15 (1.8) 15 (1.1) 0.199
Not reported 0 (0.0) 4 (0.3) nr
Values are expressed as n (%). COPD, chronic obstructive pulmonary disease; nr, statistical test not
conducted. *p-values obtained from chi-square test of hypogonadal vs. eugonadal patients.
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between groups, when BAT, FT and SHBG values were
stratiﬁed by hypogonadal status, signiﬁcant differences were
observed between groups (p 0 0.001, Table 4). There were
no signiﬁcant differences between sampling times for TT
concentration (Figure 2).
The crude prevalence rate of hypogonadism as deﬁned in
this study (TT 0300 ng/dl or current androgen treatment)
was 38.7% (95% CI, 36.6%–40.7%; Figure 3). For every
10-year increase in age, a patient’s risk of hypogonadism
increased by 17% (95% CI, 1.08–1.27). Evaluations of the
prevalence of hypogonadism using values below the reported
low reference level for FT and BAT were also evaluated.
Based on FT levels, approximately 40% of men were hypo-
gonadal (FT 052 pg/ml or current androgen treatment).
Based on BAT levels, 45% of men were hypogonadal (BAT
095 ng/dl for men 070 years of age and 060 ng/dl for
men 70 and older). The difference in the occurrence of four
of the six common symptoms of hypogonadism (decrease in
ability to perform sexually, decrease in sexual desire or
libido, physical exhaustion or lacking vitality, and decline in
general feeling of well-being) was greater in hypogonadal vs.
eugonadal patients (p 0 0.05). The presence of one or
more symptoms occurred in 66% of patients deemed hypo-
gonadal based on TT levels.
Eighty of the 2165 patients enrolled (3.7% of total) were
being treated for hypogonadism. Analysis of the data exclu-
ding these 80 patients did not signiﬁcantly alter the study
results for the overall population. In patients not currently
being treated for hypogonadism (n ¼ 2085, 96.3% of
total), the prevalence rate was 36.3% (95% CI, 34.2–
38.4%). When patient characteristics were examined in
those untreated men (i.e. who were not being treated for
hypogonadism), the relative association of hypogonadism
increased the most with increasing body mass index (BMI)
(odds ratio 1.65 per 5-unit increase) (Figure 4). The odds
ratio of having hypogonadism was 2.74 (95% CI, 2.07–
3.07) in untreated patients with a BMI  25 kg/m
2 vs.
patients with a BMI 025 kg/m
2. Men aged  65 years
were 1.26 times (95% CI, 1.08–1.28) more likely to be
hypogonadal than men aged 45–64 years. Stepwise regres-
sion analysis showed the 10-year increase in the odds ratio
was 1.21 (95% CI, 1.10–1.34). In patients not already
being treated for hypogonadism with at least one symptom,
the 10-year increase in the odds ratio was 1.33 (95% CI,
1.11–1.61).
Table 5 shows the prevalence rate of hypogonadism and
the odds ratios with speciﬁc medical conditions in the
untreated patients. The odds of hypogonadism were signiﬁ-
cantly higher in patients with hypertension, hyperlipidae-
mia, diabetes, obesity, prostate disease, and asthma or
chronic obstructive pulmonary disease (COPD) than in
patients without these conditions.
DISCUSSION
Because maintaining normal physiological concentrations of
testosterone may be important for the overall health of men
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Table 4 Testosterone levels stratiﬁed by hypogonadal status
Laboratory test (mean   SEM) Hypogonadal (TT 0300) Eugonadal (TT  300) p-value
Total testosterone (ng/dl) 245.6   4.12 (n ¼ 836) 439.9   3.52 (n ¼ 1326) N/A
Bioavailable testosterone (ng/dl) 86.1   2.4 (n ¼ 821) 108.8   1.3 (n ¼ 1317) 00.001
Free testosterone (pg/ml) 47.9   1.03 (n ¼ 834) 63.9   0.53 (n ¼ 1325) 00.001
SHBG (nmol/l) 43.7   0.74 (n ¼ 836) 68.3   0.87 (n ¼ 1326) 00.001
SEM, standard error of the mean; SHBG, sex hormone-binding globulin; TT, total testosterone; N/A, not applicable.
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Figure 2 Sampling time and total testosterone concentrations for
enrolled patients
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ant. Identifying men at risk for complications related to tes-
tosterone deﬁciency may also be important. Hypogonadism
can have a negative impact on the health and quality of life
of men because the decreases in testosterone may increase
the risk of sexual dysfunction, mood disturbances, changes
in bone mineral density and body composition, and decline
in feeling of general well-being (1,2).
In this study, based on TT 0300 ng/dl, the prevalence
of hypogonadism among men aged 45 years or older was
estimated to be 38.7%. Data from the Centers for Disease
Control and Prevention National Health Interview Survey
indicate that 74% of adult men visit a doctor’s ofﬁce
annually (11); United States census data estimate that in
2003, 48.4 million men were aged at least 45 years (12).
Using the prevalence rate observed in this study to extrapo-
late to current United States census data, it was estimated
that 13.8 million men aged  45 years visiting a primary
care doctor in the United States may be hypogonadal
(Table 6).
In an effort to determine the prevalence of hypogonadism
in clinical practice, several other studies have attempted to
identify statistical and/or clinical working deﬁnitions of
hypogonadism (7–10). A recent report from the Massachu-
setts Male Aging Study (MMAS) estimated the prevalence
rate of androgen deﬁciency to be less than that found in the
Hypogonadism in Males (HIM) study (8). However, the
MMAS used a different patient population and different
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Figure 3 Age-speciﬁc prevalence of
hypogonadism for enrolled patients
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Figure 4 Body mass index vs. total testosterone for enrolled
patients
Table 5 Prevalence rates and odds ratios
for selected risk factors in enrolled
untreated hypogonadal patients Risk factor/condition
Hypogonadism prevalence
rate (95% CI) Odds ratio (95% CI)
Obesity 52.4 (47.9–56.9) 2.38 (1.93–2.93)
Diabetes 50.0 (45.5–54.5) 2.09 (1.70–2.58)
Hypertension 42.4 (39.6–45.2) 1.84 (1.53–2.22)
Rheumatoid arthritis 47.3 (34.1–60.5) 1.59 (0.92–2.72)
Hyperlipidaemia 40.4 (37.6–43.3) 1.47 (1.23–1.76)
Osteoporosis 44.4 (25.5–64.7) 1.41 (0.64–3.01)
Asthma/COPD 43.5 (36.8–50.3) 1.40 (1.04–1.86)
Prostatic disease/disorder 41.3 (36.4–46.2) 1.29 (1.03–1.62)
Chronic pain 38.8 (33.7–44.0) 1.13 (0.89–1.44)
Headaches (within last 2 weeks) 32.1 (25.3–38.8) 0.81 (0.58–1.11)
CI, conﬁdence interval; COPD, chronic obstructive pulmonary disease.
766 HYPOGONADISM IN MALES
ª 2006 The Authors
Journal compilation ª 2006 Blackwell Publishing Ltd Int J Clin Pract, July 2006, 60, 7, 762–769criteria for diagnosing androgen deﬁciency. The MMAS was
an observational cohort study of health in a population-
based random sample of men from the Boston, MA, area
who were aged 40–70 years. Participants were studied over
7–10 years. In the MMAS, androgen deﬁciency was charac-
terised by at least three signs or symptoms and TT 0200
or 200–400 ng/dl with FT 08.9 ng/dl. In the MMAS, the
prevalence rate of androgen deﬁciency at study entry, with-
out consideration of signs or symptoms and with a cut-off
TT of 0400 ng/dl was estimated to be 25.3%; at follow-
up, the prevalence rate was 39.3%. Considering the pre-
sence of at least three signs or symptoms and TT, the
prevalence rates were 6% at baseline and 12% at follow-up.
The differences observed between the present study and the
MMAS may be related to the differences in populations stu-
died, age range, and/or criteria used to deﬁne the end point.
Despite these differences, the prevalence rate in MMAS
based on TT was close to the prevalence rate observed in
this study.
Consistent with other studies, the prevalence of hypogo-
nadism in the HIM study increased with advancing age;
men aged  65 years were 1.2 times more likely to demon-
strate hypogonadism than men aged 065 years. The odds
ratio of hypogonadism was greater with each 10-year
increase in age. Longitudinal studies in speciﬁc geographical
areas of the United States and some small cross-sectional
studies have demonstrated a decline in testosterone occur-
ring as early as age 30, but usually testosterone levels remain
within normal limits until men reach age 60 (8,13–15).
An interesting study ﬁnding was the similar prevalence of
hypogonadism between white and black participants. These
prevalence results are consistent with previous longitudinal
research in younger men that does not support differences
in testosterone levels between black and white men after
adjusting for BMI and waist circumference (16). It is well
established that the incidence of prostate cancer is higher in
black men. However, contrary to what one might expect,
black men did not have a lower prevalence rate of hypogo-
nadism (i.e. higher serum testosterone concentrations) in
the current or previous analyses (17,18).
In the present study, the most signiﬁcant differentiating
factor between hypogonadal men and eugonadal men was
BMI. Diagnosis of hypogonadism in obese men aged
 45 years should involve a number of factors. Ageing has
been shown to increase SHBG (15), thus decreasing BAT
and increasing levels of inactive testosterone (i.e. bound to
SHBG). In contrast, obesity lowers SHBG and hence TT,
but not BAT or FT (19,20). Therefore, it would be antici-
pated that hypogonadal prevalence rates calculated using FT
or BAT criteria would be lower than rates yielded by TT
(given that the SHBG is lower in the individuals with
higher BMI). However, that was not the case in this study.
Ideally, the diagnosis of hypogonadism should include com-
ponents TT and SHBG (or BAT) to determine whether the
bioactive fraction of testosterone is diminished. A measure-
ment of TT may be sufﬁcient to identify low testosterone
in the majority of patients, except in those with high BMI
(who tend to have low SHBG) or the elderly (who tend to
have elevated SHBG).
Advancing age (in 10-year increments) and increasing
BMI (in 5-unit increments) were associated with greater
prevalence rates of hypogonadism. In addition, the odds
of hypogonadism were higher in patients with a history of
hypertension, hyperlipidaemia, diabetes, and asthma or
COPD.
One strength of this study was that we enrolled a broad-
based population of men aged  45 years that was relatively
representative of the US population based on age, with the
caveat that minority groups (Hispanics and Asians) were
underrepresented as expected in usual care conditions (21).
In this study, the majority of patients presented to the
docotor’s ofﬁce for a general examination, not a speciﬁc
new problem. There were limitations that should be noted
in interpreting these data. Collecting and analysing serial
serum samples eliminates variability resulting from episodic
secretion of hormones (22). This study only evaluated sin-
gle samples. Therefore, it is reasonable to assume that some
patients with borderline values may be transiently sup-
pressed by acute conditions or stress and would not be
considered hypogonadal upon repeat testing. However,
establishing the lower threshold at 300 ng/dl vs. the refer-
ence laboratory’s lower limit of normal (350 ng/dl) may
offset some limitations surrounding persistently low TT
levels. On the other hand, the use of a single threshold TT
value for diagnosing hypogonadism may itself be a limita-
tion; there is wide variation in the individual threshold that
triggers hypogonadal symptoms (2), and some hypogonadal
patients may have been missed. Another limitation may
have been introduced because the symptoms of hypogona-
dism were not evaluated using a questionnaire validated for
the assessment of hypogonadism in men, but were recorded
by the doctor on a standardised case report form. More-
over, not all possible signs or symptoms of hypogonadism
were considered in developing the case report form used in
the study. For example, because changes in cognition and
Table 6 Estimates of hypogonadism in men aged at least
45 years visiting a doctor’s ofﬁce relative to US census data
Prevalence (%)
Men with hypogonadism
(TT 0300 ng/dl)
All men (38.7) 13.8 million
Treated men (3.7) 1.3 million
Untreated men (34.9) 12.5 million
TT, total testosterone. Data extrapolated from Lethbridge-Cejku et al. (11)
and Population Division US Census Bureau (12).
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gonadism – were not determined, the prevalence of low
TT with at least one symptom may have been underesti-
mated.
This prevalence study also captured the comorbid condi-
tions that may occur with hypogonadism in men who pre-
sent at a primary care doctor’s ofﬁce seeking treatment for
any reason, ranging from a general check-up to hyperten-
sion management. One limitation of the study is that the
checklist of comorbid conditions on the case report form
listed general conditions such as ‘prostatic disorder/disease’
rather than speciﬁc diagnoses. Nonetheless, highlighting the
diseases that are most likely to occur in hypogonadal vs.
eugonadal men may raise awareness among doctors that
hypogonadism may be an underlying comorbid condition.
CONCLUSIONS
Based on TT concentration, the prevalence of hypogona-
dism in men reporting to primary care ofﬁces was estimated
to be 38.7%. The medical conditions that occurred signiﬁ-
cantly more frequently among hypogonadal men than eugo-
nadal men included increased BMI, hypertension,
hyperlipidaemia, diabetes, and asthma or COPD. As men
age, they are susceptible to conditions that share many of
the same symptoms similar to hypogonadism. The presence
of these conditions may, in effect, mask underlying hypogo-
nadism and negatively impact quality of life.
A prevalence of this magnitude warrants consideration by
the primary care doctor as the main provider of health care;
however, controversy exists about the risks associated with
the long-term safety of testosterone replacement therapy,
particularly in older men. Therefore, men with low testos-
terone who present to the primary care ofﬁce with medical
conditions that often occur concomitantly with low test-
osterone should be evaluated and, if symptomatic and with-
out contraindications, possibly considered for treatment.
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